China’s Huagai Capital leads $146m round in HaiHe Biopharma

Medical drugs in a pharmacy. Credit: Flickr/epSos .de

Beijing-based private equity firm Huagai Capital has led a $146.6-million round in China’s HaiHe Biopharma, which is engaged in the discovery, development and commercialisation of drugs for cancer treatment, according to an official release.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.